


Stereochemistry abstracts

Gelson J. Andrade Conceição, Paulo J. S. Moran and  
J. Augusto R. Rodrigues\*

Tetrahedron: Asymmetry 14 (2003) 2327



C<sub>9</sub>H<sub>10</sub>O<sub>2</sub>  
(1S,2R)-1,2-Indandiol

E.e. >99%


[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -38.8 (c 1, CHCl<sub>3</sub>)

Source of chirality: biocatalytic reduction

Absolute configuration: (1S,2R)

Valery V. Dunina,\* Elena D. Razmyslova, Ol'ga N. Gorunova,  
Michail V. Livantsov and Yuri K. Grishin

Tetrahedron: Asymmetry 14 (2003) 2331



C<sub>22</sub>H<sub>32</sub>C<sub>2</sub>N<sub>2</sub>Pd<sub>2</sub>

(R<sub>C</sub>,R<sub>C</sub>)-Di- $\mu$ -chlorobis[2-{1-amino-2,2-dimethylpropyl}phenyl-C,N]dipalladium(II)

Ee >98% (based on enantiomeric purity of the starting amine)


[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -146 (c 0.4, Py/CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: optically active starting  $\alpha$ -phenylneopentylamine

Absolute configuration: (R<sub>C</sub>R<sub>C</sub>)

V. Grosset, D. Danvy and M. Capet\*

Tetrahedron: Asymmetry 14 (2003) 2335



C<sub>20</sub>H<sub>21</sub>NO<sub>5</sub>S

(R)-3-Acetylsulfanyl-2-benzyloxycarbonylaminopropylbenzo[1,3]dioxolane

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +7.6 (c 1.0, CHCl<sub>3</sub>)   [ $\alpha$ ]<sub>365</sub><sup>20</sup> = +19.7


[ $\alpha$ ]<sub>436</sub><sup>20</sup> = +14.0   [ $\alpha$ ]<sub>546</sub><sup>20</sup> = +8.8   [ $\alpha$ ]<sub>589</sub><sup>20</sup> = +7.7

Source of chirality: resolution of precursor

Absolute stereochemistry: (S)

V. Grosset, D. Danvy and M. Capet\*

Tetrahedron: Asymmetry 14 (2003) 2335




C<sub>23</sub>H<sub>25</sub>NO<sub>6</sub>S

(S)-2-[(S)-2-Acetylsulfanyl methyl-3-benzo[1,3]dioxol-5-ylpropionylamino]propionic acid benzyl ester

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -50.6 (c 1.3, MeOH)

Source of chirality: resolution of precursor and chiral pool

Absolute configuration: (S,S)



C<sub>6</sub>H<sub>10</sub>O<sub>2</sub>


(2E,4R)-4-Hydroxy-2-hexenal

Ee = 93%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -52.3 (c 1.21, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 4R



C<sub>7</sub>H<sub>12</sub>O<sub>4</sub>


Methyl (2E,4S)-4-hydroperoxy-2-hexenoate

Ee = 93%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -15.1 (c 3.00, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 4S



C<sub>7</sub>H<sub>12</sub>O<sub>3</sub>


Methyl (2E,4R)-4-hydroxy-2-hexenoate

Ee = 97%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -27.8 (c 2.10, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 4R



C<sub>8</sub>H<sub>14</sub>O<sub>4</sub>


Ethyl (2E,4S)-4-hydroperoxy-2-hexenoate

Ee >99%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -20.3 (c 1.00, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 4S



C<sub>8</sub>H<sub>14</sub>O<sub>3</sub>


Ethyl (2E,4S)-4-hydroxy-2-hexenoate

Ee >99%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +25.0 (c 1.83, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 4S



C<sub>9</sub>H<sub>16</sub>O<sub>4</sub>


Isopropyl (2E,4S)-4-hydroperoxy-2-hexenoate

Ee = 98%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -19.8 (c 1.00, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 4S



C<sub>9</sub>H<sub>16</sub>O<sub>3</sub>


Isopropyl (2E,4R)-4-hydroxy-2-hexenoate

Ee = 98%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -25.2 (c 1.00, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 4R



C<sub>9</sub>H<sub>16</sub>O<sub>3</sub>


t-Butyl (2E,4R)-4-hydroxy-2-hexenoate

Ee = 95%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -15.0 (c 1.00, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 4R



C<sub>6</sub>H<sub>10</sub>O<sub>3</sub>


(2E,4S)-4-Hydroperoxy-2-hexenal

Ee = 97%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -24.4 (c 1.56, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 4S



C<sub>6</sub>H<sub>10</sub>O<sub>2</sub>


(2E,4S)-4-Hydroxy-2-hexenal

Ee = 97%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +55.0 (c 0.73, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 4S



C<sub>19</sub>H<sub>20</sub>O<sub>3</sub>


Chircanine B

E.e. = 97%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -12 (c 0.9, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: S




C<sub>27</sub>H<sub>27</sub>O<sub>4</sub>PS

(1S,3R,6R,8R,9R)-2,7-Dioxa-3-[2-(diphenylphosphino)phenyl]-8,9-O-isopropylidenethiabicyclo[4.3.0]nonane

Ee = 100%

[ $\alpha$ ]<sub>D</sub><sup>23</sup> = -78.0 (c 1.0, CHCl<sub>3</sub>)

Source of chirality: 1,2-O-isopropylidene-D-xylofuranose




C<sub>30</sub>H<sub>34</sub>NO<sub>4</sub>P

(1*S*,3*S*,6*R*,8*R*,9*R*)-4-Aza-2,7-dioxa-3-[2-(diphenylphosphino)phenyl]-4-isopropyl-8,9-*O*-isopropylidenebicyclo[4.3.0]nonane

Ee = 100%

[ $\alpha$ ]<sub>D</sub><sup>23</sup> = +17.9 (*c* 1.2, CHCl<sub>3</sub>)

Source of chirality: 1,2-*O*-isopropylidene-D-xylofuranose




C<sub>34</sub>H<sub>34</sub>NO<sub>4</sub>P

(1*S*,3*S*,6*R*,8*R*,9*R*)-4-Aza-4-benzyl-2,7-dioxa-3-[2-(diphenylphosphino)phenyl]-4-isopropyl-8,9-*O*-isopropylidenebicyclo[4.3.0]nonane

Ee = 100%

[ $\alpha$ ]<sub>D</sub><sup>23</sup> = +79.8 (*c* 1.3, CHCl<sub>3</sub>)

Source of chirality: 1,2-*O*-isopropylidene-D-xylofuranose




C<sub>38</sub>H<sub>36</sub>NO<sub>4</sub>P

(1*S*,3*S*,6*R*,8*R*,9*R*)-4-Aza-4-benzyl-2,7-dioxa-3-[2-(diphenylphosphino)phenyl]-4-isopropyl-8,9-*O*-isopropylidene-4-(1-naphthyl)-methylbicyclo[4.3.0]nonane

Ee = 100%

[ $\alpha$ ]<sub>D</sub><sup>23</sup> = +73.5 (*c* 1.2, CHCl<sub>3</sub>)

Source of chirality: 1,2-*O*-isopropylidene-D-xylofuranose




C<sub>34</sub>H<sub>34</sub>NO<sub>4</sub>P

(1*S*,3*S*,6*R*,8*R*,9*R*)-4-Aza-2,7-dioxa-3-[2-(diphenylphosphino)phenyl]-4-isopropyl-8,9-*O*-isopropylidene-4-(4(*R*)-phenylethyl)bicyclo[4.3.0]nonane


Ee = 100%

[ $\alpha$ ]<sub>D</sub><sup>23</sup> = +46.9 (*c* 1.3, CHCl<sub>3</sub>)


Source of chirality: 1,2-*O*-isopropylidene-D-xylofuranose

 $C_{44}H_{52}N_2O_2$ 


(S,S)-2-[Bis-(4-methyl-benzyl)-amino]-3-(3-{2-[bis-(4-methyl-benzyl)-amino]-3-hydroxy-propyl}-phenyl)-propan-1-ol

 $[\alpha]_D^{21} = +17.9$  (*c* 1.4, EtOH) $C_{25}H_{29}NO$ 

(S)-2-[Bis-(4-methyl-benzyl)-amino]-3-phenyl-propan-1-ol


 $[\alpha]_D^{21} = +12.7$  (*c* 11.3, CHCl<sub>3</sub>) $C_{37}H_{52}O_{24}$ 

Methyl 2,4,6-tri-O-acetyl-3-O-[3,4,6-tri-O-acetyl-2-O-(2,3,4-tri-O-acetyl-alpha-L-fucopyranosyl)-beta-D-galactopyranosyl]-beta-D-galactopyranoside

 $[\alpha]_D^{20} = -33.0$  (*c* 0.10, CHCl<sub>3</sub>) $C_{30}H_{42}O_{20}$ 

1,2,3,5,6-Penta-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-beta-D-galactopyranosyl)-D-mannitol


 $[\alpha]_D^{20} = -11.4$  (*c* 0.36, CHCl<sub>3</sub>)



$[\alpha]_D^{20} = -36.7$  (*c* 0.09, CHCl<sub>3</sub>)

C<sub>40</sub>H<sub>56</sub>O<sub>26</sub>

1,2,3,5,6-Penta-O-acetyl-4-O-[3,4,6-tri-O-acetyl-2-O-(2,3,4-tri-O-acetyl- $\alpha$ -L-fuco-pyranosyl)- $\beta$ -D-galactopyranosyl]-D-mannitol




E.e. >99%

$[\alpha]_D^{25} = +212$  (*c* 0.70, CHCl<sub>3</sub>)

Source of chirality: (S)-(+)-4-ethenyl[2.2]paracyclophane

(S)-(+)-5-(Acetoxy)-7-[(E)-2-tricyclo[8.2.2.2<sup>4,7</sup>]hexadeca-1(12),4,6,10,13,15-hexaen-5-ylvinyl]isoquinolin-8-yl acetate




E.e. >99%

$[\alpha]_D^{25} = -67$  (*c* 0.33, CHCl<sub>3</sub>)

Source of chirality: (S)-(+)-4-ethenyl[2.2]paracyclophane

(S,R)-(-)-2-Tricyclo[8.2.2.2<sup>4,7</sup>]hexadeca-1(12),4,6,10,13,15-hexaen-5-yl-2,3-dihydrofuro[2,3-f]quinolin-5-ol




E.e. >99%

$[\alpha]_D^{25} = +84$  (*c* 0.36, CHCl<sub>3</sub>)

Source of chirality: (S)-(+)-4-ethenyl[2.2]paracyclophane

C<sub>28</sub>H<sub>24</sub>O<sub>2</sub>  
(R,S,S)-(+)-2,3,8,9,11,12,12a,18a-Octahydro-1,10:4,7-diethenocyclododeca[a]anthracene-13,18-dione




(R)-3-(3-Hydroxy-2-oxotetrahydrofuran-3-yl)propanoic acid

Ee >95%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +13 (c 2.04, MeOH)

Source of chirality: asymmetric synthesis

Absolute configuration: 3*R*




(R)-1,7-Dioxaspiro[4.4]nonane-2,6-dione

Ee >95%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +72 (c 1.08, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 5*R*




(4*R*,5*S*)-4-Benzyl-1,7-dioxaspiro[4.4]nonane-2,6-dione

Ee = 86%

[ $\alpha$ ]<sub>D</sub><sup>21</sup> = -42 (c 4.09, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 4*R*,5*S*




(4*S*,5*S*)-4-Benzyl-1,7-dioxaspiro[4.4]nonane-2,6-dione

Ee = 93%

[ $\alpha$ ]<sub>D</sub><sup>21</sup> = +153 (c 0.89, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 4*S*,5*S*




(S)-3-Methyl-2-phenylbutylamine

Ee = 96%

$[\alpha]_D^{20} = -17.6$  (*c* 0.81, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 3*S*




(2*R*,3*R*)-3-Phenyl-azetidine-2-carboxylic acid

E.e. >95%

$[\alpha]_D^{20} = -118$  (*c* 2, H<sub>2</sub>O)

Source of chirality: (R)-Phenylglycinol

Absolute configuration: (2*R*,3*R*)




(2*S*,3*S*,4*S*)-(1,4-Dimethyl-3-phenyl-azetidine-2-yl)-carboxylic acid

E.e. >95%

$[\alpha]_D^{20} = -61$  (*c* 0.8, H<sub>2</sub>O)

Source of chirality: (1*R*,2*S*)-Ephedrine

Absolute configuration: (2*S*,3*S*,4*S*)




(2*R*,3*S*,4*S*)-(1,4-Dimethyl-3-phenyl-azetidine-2-yl)-carboxylic acid

E.e. >95%

$[\alpha]_D^{20} = +64$  (*c* 1.2, H<sub>2</sub>O)

Source of chirality: (1*R*,2*S*)-Ephedrine

Absolute configuration: (2*S*,3*S*,4*S*)



(1*R*,2*R*,4*S*)-4-Hydroxy-2-methyl-2-*p*-tolyl-cyclopentanecarboxylic acid ethyl ester

Ee >98% [by chiral HPLC]


$[\alpha]_D^{20} = -93.3$  (*c* 1.0, CHCl<sub>3</sub>)

Source of chirality: CAL-B mediated kinetic resolution

Absolute configuration: (1*R*,2*R*,4*S*)

Samir Acherar, Gérard Audran, Nicolas Vanthuyne  
and Honoré Monti\*

Tetrahedron: Asymmetry 14 (2003) 2413



(1*S*,2*S*,4*R*)-4-Acetoxy-2-methyl-2-*p*-tolyl-cyclopentanecarboxylic acid ethyl ester

Ee >98% [by chiral HPLC]


$[\alpha]_D^{20} = +50.6$  (*c* 1.0, CHCl<sub>3</sub>)

Source of chirality: CAL-B mediated kinetic resolution

Absolute configuration: (1*S*,2*S*,4*R*)

Samir Acherar, Gérard Audran, Nicolas Vanthuyne  
and Honoré Monti\*

Tetrahedron: Asymmetry 14 (2003) 2413



(1*S*,4*R*,1'*S*,3'*R*,4'*R*)-4,7,7-trimethyl-3-oxo-2-oxa-bicyclo[2.2.1]heptane-1-carboxylic acid 4'-ethoxycarbonyl-3'-methyl-3'-*p*-tolyl-1'-cyclopentyl ester

Ee >98% [by chiral HPLC]


$[\alpha]_D^{20} = -27.5$  (*c* 1.0, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (1*S*,4*R*,1'*S*,3'*R*,4'*R*)

Samir Acherar, Gérard Audran, Nicolas Vanthuyne  
and Honoré Monti\*

Tetrahedron: Asymmetry 14 (2003) 2413




(1*R*,2*R*,4*S*)-2-Methyl-4-methylsulfanylthiocarboxyxy-2-*p*-tolyl-cyclopentanecarboxylic acid ethyl ester

Ee >98% [by chiral HPLC]

$[\alpha]_D^{20} = -37.7$  (*c* 1.0, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (1*R*,2*R*,4*S*)



C<sub>16</sub>H<sub>22</sub>O<sub>2</sub>

(1*R*,2*R*)-2-Methyl-2-*p*-tolyl-cyclopentanecarboxylic acid ethyl ester


Ee >98% [by chiral HPLC]

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -98.0 (*c* 1.0, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (1*R*,2*R*)

Ugo Chiacchio,\* Luisa Borrello, Daniela Iannazzo, Pedro Merino,\*  
Anna Piperno, Antonio Rescifina, Barbara Richichi and  
Giovanni Romeo\*



C<sub>14</sub>H<sub>23</sub>NO<sub>7</sub>


Ethyl (3*S*,5*S*)-5-(acetoxy)-3-[(4*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-methylisoxazolidine-5-carboxylate

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -9.7 (*c* 0.36, CHCl<sub>3</sub>)

Source of chirality: D-glyceraldehyde

Absolute configuration: 2*R*

Ugo Chiacchio,\* Luisa Borrello, Daniela Iannazzo, Pedro Merino,\*  
Anna Piperno, Antonio Rescifina, Barbara Richichi and  
Giovanni Romeo\*



C<sub>14</sub>H<sub>23</sub>NO<sub>7</sub>


Ethyl (3*S*,5*R*)-5-(acetoxy)-3-[(4*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-methylisoxazolidine-5-carboxylate

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +11.7 (*c* 0.13, CHCl<sub>3</sub>)

Source of chirality: D-glyceraldehyde

Absolute configuration: 2*R*

Ugo Chiacchio,\* Luisa Borrello, Daniela Iannazzo, Pedro Merino,\*  
Anna Piperno, Antonio Rescifina, Barbara Richichi and  
Giovanni Romeo\*



C<sub>14</sub>H<sub>23</sub>NO<sub>7</sub>

Ethyl (3*R*,5*R*)-5-(acetoxy)-3-[(4*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-methylisoxazolidine-5-carboxylate


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -7.3 (*c* 0.12, CHCl<sub>3</sub>)

Source of chirality: D-glyceraldehyde

Absolute configuration: 2*R*

Ugo Chiacchio,\* Luisa Borrello, Daniela Iannazzo, Pedro Merino,\* Anna Piperno, Antonio Rescifina, Barbara Richichi and Giovanni Romeo\*

*Tetrahedron: Asymmetry* 14 (2003) 2419



Ethyl (3S,5S)-3-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-methyl-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)isoxazolidine-5-carboxylate


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -4.5 (*c* 0.56, CHCl<sub>3</sub>)

Source of chirality: D-glyceraldehyde

Absolute configuration: 2*R*

Ugo Chiacchio,\* Luisa Borrello, Daniela Iannazzo, Pedro Merino,\* Anna Piperno, Antonio Rescifina, Barbara Richichi and Giovanni Romeo\*

*Tetrahedron: Asymmetry* 14 (2003) 2419



Ethyl (3*R*,5*R*)-3-[(4*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-methyl-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)isoxazolidine-5-carboxylate


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -7.7 (*c* 0.58, CHCl<sub>3</sub>)

Source of chirality: D-glyceraldehyde

Absolute configuration: 2*R*

Ugo Chiacchio,\* Luisa Borrello, Daniela Iannazzo, Pedro Merino,\* Anna Piperno, Antonio Rescifina, Barbara Richichi and Giovanni Romeo\*

*Tetrahedron: Asymmetry* 14 (2003) 2419



Ethyl (3*S*,5*S*)-5-[4-(acetylamino)-2-oxopyrimidin-1(2*H*)-yl]-3-[(4*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-methylisoxazolidine-5-carboxylate


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +18.3 (*c* 1.20, CHCl<sub>3</sub>)

Source of chirality: D-glyceraldehyde

Absolute configuration: 2*R*

Ugo Chiacchio,\* Luisa Borrello, Daniela Iannazzo, Pedro Merino,\* Anna Piperno, Antonio Rescifina, Barbara Richichi and Giovanni Romeo\*

*Tetrahedron: Asymmetry* 14 (2003) 2419



Ethyl (3*R*,5*R*)-5-[4-(acetylamino)-2-oxopyrimidin-1(2*H*)-yl]-3-[(4*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-methylisoxazolidine-5-carboxylate


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +12.5 (*c* 0.12, CHCl<sub>3</sub>)

Source of chirality: D-glyceraldehyde

Absolute configuration: 2*R*

Ugo Chiacchio,\* Luisa Borrello, Daniela Iannazzo, Pedro Merino,\* Anna Piperno, Antonio Rescifina, Barbara Richichi and Giovanni Romeo\*

*Tetrahedron: Asymmetry* 14 (2003) 2419



Ethyl (3*S*,5*S*)-3-[(4*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-2-methylisoxazolidine-5-carboxylate



[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +6.4 (*c* 0.31, CHCl<sub>3</sub>)

Source of chirality: D-glyceraldehyde

Absolute configuration: 2*R*

Ugo Chiacchio,\* Luisa Borrello, Daniela Iannazzo, Pedro Merino,\* Anna Piperno, Antonio Rescifina, Barbara Richichi and Giovanni Romeo\*

*Tetrahedron: Asymmetry* 14 (2003) 2419



Ethyl (3*R*,5*R*)-3-[(4*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-2-methylisoxazolidine-5-carboxylate


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +6.5 (*c* 0.85, CHCl<sub>3</sub>)

Source of chirality: D-glyceraldehyde

Absolute configuration: 2*R*

Ugo Chiacchio,\* Luisa Borrello, Daniela Iannazzo, Pedro Merino,\* Anna Piperno, Antonio Rescifina, Barbara Richichi and Giovanni Romeo\*

*Tetrahedron: Asymmetry* 14 (2003) 2419



Ethyl (3*S*,5*S*)-3-(hydroxymethyl)-2-methyl-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)isoxazolidine-5-carboxylate


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +13.1 (*c* 0.96, CHCl<sub>3</sub>)

Source of chirality: D-glyceraldehyde

Absolute configuration: 2*R*

Ugo Chiacchio,\* Luisa Borrello, Daniela Iannazzo, Pedro Merino,\* Anna Piperno, Antonio Rescifina, Barbara Richichi and Giovanni Romeo\*

*Tetrahedron: Asymmetry* 14 (2003) 2419




Ethyl (3*R*,5*R*)-3-(hydroxymethyl)-2-methyl-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)isoxazolidine-5-carboxylate

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -12.8 (*c* 0.85, CHCl<sub>3</sub>)

Source of chirality: D-glyceraldehyde

Absolute configuration: 2*R*




Ee = 91%

$[\alpha]_D^{20} = -2.8$  (*c* 1.45, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: (*S*)




Ee = 98%

$[\alpha]_D^{20} = +12.0$  (*c* 1.40, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: (*S*)




E.e. = 95%

$[\alpha]_D = -20.9$  (*c* 0.76, MeOH)

Source of chirality: (-)-*S*-verbenone

Absolute configuration: 1'*R*,3'*R*




E.e. = 95%

$[\alpha]_D = -8.6$  (*c* 0.58, MeOH)

Source of chirality: (-)-*S*-verbenone

Absolute configuration: 1'*R*,3'*R*




$C_{29}H_{34}N_2O_6$   
( $1'R,3'R$ )-3-(3'-Acetyl-2',2'-dimethylcyclobutyl)-2-benzyloxycarbonylamino-(1''S)-N-(1''-benzyl-1''-methoxycarbonyl)methyl-2-(Z)-propenamide

E.e. = 95%

$[\alpha]_D = -30$  ( $c$  0.10, MeOH)

Source of chirality: ( $-$ )-*S*-verbenone

Absolute configuration:  $1'R,3'R$




$C_{22}H_{30}N_2O_6$   
( $2R,1'R,3'R$ )-3-(3'-Acetyl-2',2'-dimethylcyclobutyl)-2-benzyloxycarbonylamino-*N*-methoxycarbonylmethyl-propamide

E.e. = 95%

$[\alpha]_D = +32$  ( $c$  0.1, MeOH)

Source of chirality: ( $-$ )-*S*-verbenone

Absolute configuration:  $2R,1'R,3'R$




$C_{29}H_{36}N_2O_6$   
( $2R,1'R,3'R$ )-3-(3'-Acetyl-2',2'-dimethylcyclobutyl)-2-benzyloxycarbonylamino-(1''S)-N-(1''-benzyl-1''-methoxycarbonyl)methyl-propamide

E.e. = 95%

$[\alpha]_D = -7.7$  ( $c$  1.2, MeOH)

Source of chirality: ( $-$ )-*S*-verbenone

Absolute configuration:  $2R,1'R,3'R$




$C_{23}H_{38}N_2O_2$   
(*S*)-2-[7-(5-Benzylxypentyl)-3,7-diazabicyclo[3.3.1]non-3-yl]-butan-2-ol

$[\alpha]_D^{20} + 36$  ( $c$  0.33, EtOH)

Source of chirality: (*S*)-2-ethyloxirane

Absolute configuration: *S*




$C_{27}H_{38}N_2O_2$   
(*R*)-2-[7-(5-Benzylloxypentyl)-3,7-diazabicyclo[3.3.1]non-3-yl]-1-phenylethanol

$[\alpha]_D^{20} = -82$  (*c* 0.33, EtOH)

Source of chirality: (*R*)-2-phenyloxirane

Absolute configuration: *R*




$C_{14}H_{14}O_3$   
(*S*)-(+)-6-Methoxy- $\alpha$ -methyl-2-naphthaleneacetic acid

Ee >99% (chiral HPLC)

$[\alpha]_D = +66.6$  (*c* 1, CHCl<sub>3</sub>)

Source of chirality: enzyme-catalysed hydrolysis




$C_{18}H_{22}O_4$   
(1*S*,1'*S*)-1,1'-(6,6'-Dimethoxy-1,1'-biphenyl-3,3'-diyl)diethanol

E.e. >99%, 94:6 diastereoisomeric ratio

$[\alpha]_D^{22} = -35.2$  (*c* 0.25, CHCl<sub>3</sub>)

Source of chirality: asymmetric reduction

Absolute configuration: 1*S*,1'*S*



$C_{20}H_{26}O_6$   
(1*S*,1'*S*)-1,1'-(5,5',6,6'-Tetramethoxy-1,1'-biphenyl-3,3'-diyl)diethanol

E.e. >99%, 94:6 diastereoisomeric ratio


$[\alpha]_D^{22} = -29.6$  (*c* 0.66, CHCl<sub>3</sub>)

Source of chirality: asymmetric reduction

Absolute configuration: 1*S*,1'*S*

Giovanna Delogu,\* Maria Antonietta Dettori, Angela Patti,\*  
Sonia Pedotti, Alessandra Forni and Gianluigi Casalone

*Tetrahedron: Asymmetry* 14 (2003) 2467



(1*S*,1'*S*)-1,1'-(6,6'-Dimethoxy-1,1'-biphenyl-3,3'-diyl)diethanol-bis(1*R*,2*S*,5*R*)-mentylcarbonate

E.e. >99%, 94:6 diastereoisomeric ratio


[ $\alpha$ ]<sub>D</sub><sup>22</sup> = -68.5 (*c* 0.87, CHCl<sub>3</sub>)

Source of chirality: asymmetric reduction

Absolute configuration: 1*S*,1'*S*

Giovanna Delogu,\* Maria Antonietta Dettori, Angela Patti,\*  
Sonia Pedotti, Alessandra Forni and Gianluigi Casalone

*Tetrahedron: Asymmetry* 14 (2003) 2467



(1*S*,1'*S*)-1,1'-(5,5',6,6'-Tetramethoxy-1,1'-biphenyl-3,3'-diyl)diethanol-bis-(1*S*,4*R*)-camphanate ester

E.e. >99%


[ $\alpha$ ]<sub>D</sub><sup>22</sup> = -52.5 (*c* 0.86, CHCl<sub>3</sub>)

Source of chirality: asymmetric reduction

Absolute configuration: 1*S*,1'*S*

Siegfried Peters, Frieder W. Lichtenthaler\* and Hans J. Lindner

*Tetrahedron: Asymmetry* 14 (2003) 2475




3*R*-[1'R,2'-Di-hydroxyethyl]-1*S*-methyl-2,7-dioxabicyclo[3.2.1]octane-4*S*,5*S*-diol

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -27.4 (*c* 1.0, MeOH)

Source of chirality: D-fructose

Siegfried Peters, Frieder W. Lichtenthaler\* and Hans J. Lindner

*Tetrahedron: Asymmetry* 14 (2003) 2475




4*S*,5*S*-Bis-acetoxy-3*R*-[1'R,2'-bis-acetoxyethyl]-1*S*-methyl-2,7-dioxabicyclo[3.2.1]octane

Mp = 95–97°C

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +1.1 (*c* 1.0, CHCl<sub>3</sub>)

Source of chirality: D-fructose




$C_{18}H_{23}NO_3$   
(1*S*,2*R*)-*N*-(3,5-Dimethoxy)benzyl-2-amino-1-phenyl-1-propanol

$[\alpha]_D^{23} = -14.0$  (*c* 0.2, acetone)

Source of chirality: (1*S*,2*R*)-norephedrine

Absolute configuration: 1*S*,2*R*




$C_{30}H_{31}NO_3$   
(1*S*,2*R*)-*N*-(3,5-Dibenzoyloxy)benzyl-2-amino-1-phenyl-1-propanol

$[\alpha]_D^{23} = -8.2$  (*c* 0.5, acetone)

Source of chirality: (1*S*,2*R*)-norephedrine

Absolute configuration: 1*S*,2*R*




$C_{58}H_{55}NO_7$   
(1*S*,2*R*)-*N*-[3,5-Di(3,5-dibenzoyloxy)benzyloxy]benzyl-2-amino-1-phenyl-1-propanol

$[\alpha]_D^{23} = -4.1$  (*c* 0.5, acetone)

Source of chirality: (1*S*,2*R*)-norephedrine

Absolute configuration: 1*S*,2*R*




$C_{114}H_{103}NO_{15}$   
(1*S*,2*R*)-*N*-[3,5-Di[3,5-di(3,5-dibenzoyloxy)benzyloxy]benzyloxy]benzyl-2-amino-1-phenyl-1-propanol

$[\alpha]_D^{23} = +2.0$  (*c* 0.6,  $CH_2Cl_2$ )

Source of chirality: (1*S*,2*R*)-norephedrine

Absolute configuration: 1*S*,2*R*




C<sub>22</sub>H<sub>31</sub>NO<sub>5</sub>  
(1S,2R)-N-[3,5-Di(2-methoxyethoxy)]benzyl-2-amino-1-phenyl-1-propanol

[ $\alpha$ ]<sub>D</sub><sup>23</sup> = -7.9 (c 0.6, EtOH)

Source of chirality: (1S,2R)-norephedrine

Absolute configuration: 1S,2R




C<sub>42</sub>H<sub>55</sub>NO<sub>11</sub>  
(1S,2R)-N-[3,5-Di[3,5-di(2-methoxyethoxy)]benzyloxy]benzyl-2-amino-1-phenyl-1-propanol

[ $\alpha$ ]<sub>D</sub><sup>23</sup> = +3.5 (c 1.0, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: (1S,2R)-norephedrine

Absolute configuration: 1S,2R



C<sub>82</sub>H<sub>103</sub>NO<sub>23</sub>  
(1S,2R)-N-[3,5-Di[3,5-di[3,5-di(2-methoxyethoxy)]benzyloxy]benzyloxy]benzyl-2-amino-1-phenyl-1-propanol

[ $\alpha$ ]<sub>D</sub><sup>23</sup> = +2.0 (c 1.5, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: (1S,2R)-norephedrine

Absolute configuration: 1S,2R